https://orcid.org/0000-0003-3579-7921
References
- Abdellatif KRA , BakrRB. New advances in synthesis and clinical aspects of pyrazolo[3,4-d]pyrimidine scaffolds. Bioorg. Chem.78, 341–357 (2018).
- Schenone S , RadiM , MusumeciF , BrulloC , BottaM. Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies. Chem. Rev.114(14), 7189–7238 (2014).
- Greco C , CataniaR , BalaccoDLet al. Synthesis and antibacterial evaluation of new pyrazolo[3,4-d]pyrimidines kinase inhibitors. Molecules25(22), 5354 (2020).
- Tageldin GN , FahmySM , AshourHM , KhalilMA , NassraRA , LaboutaIM. Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidines as anti-inflammatory agents. Bioorg. Chem.78, 358–371 (2018).
- Gilbert AM , NowakP , BrooijmansNet al. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-α: hit to lead studies. Bioorg. Med. Chem. Lett.20(2), 636–639 (2010).
- Cacciari B , RomagnoliR , RomaniA , TrentiniA , HanauS. Thio-substituted derivatives of 4-amino-pyrazolo[3,4-d]pyrimidine-6-thiol as antiproliferative agents. Future Med. Chem.13(18), 1515–1530 (2021).
- Sies H , JonesDP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol.21(7), 363–383 (2020).
- Abdelgawad MA , ElkanziNAA , NaylAAet al. Targeting tumor cells with pyrazolo[3,4-d]pyrimidine scaffold: a literature review on synthetic approaches, structure activity relationship, structural and target-based mechanisms. Arab. J. Chem.15(5), 103781 (2022).
- Kostić A , JovanovićStojanov S , Podolski-RenićAet al. Pyrazolo[3,4-d]pyrimidine tyrosine kinase inhibitors induce oxidative stress in patient-derived glioblastoma cells. Brain Sci.11(7), 884–898 (2021).
- Jin Y , CaiQ , ShenoyAKet al. Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation. Oncotarget7(18), 25113–25124 (2016).
- Canovas B , NebredaAR. Diversity and versatility of p38 kinase signalling in health and disease. Nat. Rev. Mol. Cell Biol.22(5), 346–366 (2021).
- Atatreh N , YoussefAM , GhattasMAet al. Anti-inflammatory drug approach: synthesis and biological evaluation of novel pyrazolo[3,4-d]pyrimidine compounds. Bioorg. Chem.86, 393–400 (2019).
- Abdelall EKA , LamiePF , AhmedAKM , El-NahassE-S. COX-1/COX-2 inhibition assays and histopathological study of the new designed anti-inflammatory agent with a pyrazolopyrimidine core. Bioorg. Chem.86, 235–253 (2019).
- Lee JA , KwonY-W , KimHRet al. A novel pyrazolo[3,4-d]pyrimidine induces heme oxygenase-1 and exerts anti-inflammatory and neuroprotective effects. Mol. Cells45(3), 134–147 (2022).
- Silvestro S , MazzonE. Nrf2 activation: involvement in central nervous system traumatic injuries. a promising therapeutic target of natural compounds. Int. J. Mol. Sci.24(1), 199–223 (2022).
- Vignaroli G , ZamperiniC , DreassiEet al. Pyrazolo[3,4-d]pyrimidine prodrugs: strategic optimization of the aqueous solubility of dual Src/Abl inhibitors. ACS Med. Chem. Lett.4(7), 622–626 (2013).
- Dreassi E , ZizzariAT , MoriMet al. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors. Eur. J. Med. Chem.45(12), 5958–5964 (2010).
- Vignaroli G , CalandroP , ZamperiniCet al. Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery. Sci. Rep.6(1), 21509 (2016).
- Wang D , SunY , LiuY , MengF , LeeRJ. Clinical translation of immunoliposomes for cancer therapy: recent perspectives. Expert Opin. Drug Deliv.15(9), 893–903 (2018).
- Rango E , PastorinoF , BrignoleCet al. The pyrazolo[3,4-d]pyrimidine derivative Si306 encapsulated into anti-GD2-immunoliposomes as therapeutic treatment of neuroblastoma. Biomedicines10(3), 659 (2022).